Clear, simple language improves patient safety

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) were initially indicated as blood glucose-lowering drugs for type 2 diabetes. They are now widely used as first-line therapies for various indications, particularly heart failure and chronic kidney disease. Although their growing importance is increasingly supported by data from clinical trials, their specific side effect profile requires thorough patient education to ensure safe and effective use.